Media and Public Relations
Please click on Press Releases, Business Opportunities, or Publications for more information about our company, co-development opportunities, our lead products, and/or our core biotechnologies.
Investor Relations
The Company
Epeius Biotechnologies Corporation is a privately held specialty biopharmaceutical company whose mission is to advance genetic medicine by developing and commercializing its proprietary tumor-targeting technologies.
The Platform
The Epeius Targeted Delivery System (TDS) - enables stealth nanoparticles to be injected directly into a vein to deliver therapeutic genes selectively to cancerous lesions, while sparing normal cells and healthy tissues.
The Market
The treatment of primary and metastatic cancer and all solid tumors. Tumor-targeted anti-cancer agents are more effective and less toxic than conventional medicines and chemotherapy, by design.
Epeius is bringing genetic medicine to the cancer patient with Rexin-G®, the world's first tumor-targeted genetic medicine
Business Strategy
Driven by a longstanding passion to develop a superior treatment for metastatic cancer, the visionary business builders of Epeius Biotech invented and perfected the sophisticated tumor-targeting technologies that will serve to revolutionize the fields of medical delivery and cancer therapy. Following landmark clinical trials, which demonstrated the overall safety and single-agent efficacy of Rexin-G, the management of Epeius undertook the arduous task of bringing the world’s first and, so-far, only targeted genetic medicine to cancer patients around the world. By serving this unmet-medical need, Epeius Biotech elected to lead-by-example, with first-mover-advantages, best-of-breed biotechnologies, exclusive licenses for all its core biotechnologies, and an enviable IP estate.
In addition to developing all the enabling biotechnologies embodied in Rexin-G, its lead product, scientists at Epeius Biotech have raised the bar several orders of magnitude—in terms of bio-manufacturing and bio-process development—to the point that it represents a new state-of-the-art in the production of genetic medicine, along with substantial economies-of-scale. The business strategy is ultimately a Diversified Revenue Model, based on (i) the commercialization of its high-value medical products for the most serious of disease indications, (ii) the out-licensing of its unmatched biotechnologies for tumor-targeting and new pathotropic (disease-seeking) medicines, and (iii) strategic alliances and/or partnerships with the biopharmaceutical industry for the manufacture, testing, sales, and distribution of its tumor-targeted oncology products worldwide.
Business Execution
Epeius Biotech has achieved continued success in a competitive and unforgiving field of human endeavor, where many others have simply failed to deliver. With unprecedented demonstrations of broad-spectrum anti-cancer activity and profound single-agent efficacy, its lead product answers the challenge of “Gene Delivery, Delivery, Delivery!” with profound demonstrations of “Survival, Survival, Survival!” Epeius Biotech was granted Orphan Drug status (and thereby market protections) by the U.S. FDA, as well as international patent protection for its core biotechnologies and for its pioneering demonstrations of safe and effective tumor-targeted gene delivery in vivo (in the human body).
With the recent commercialization of Rexin-G in the Philippines, Epeius Biotech is well-positioned to serve the cancer patient by fulfilling a great unmet medical need, while placing this biotechnology corporation at the cusp of commercial and financial success. With the generation of early revenues, Epeius now enjoys the high-growth potential of an innovative biotechnology company with the lowered risk profile of a biopharmaceutical company with a high-value lead product. Epeius remains highly-selective in terms of the quality of its partners and investors.
